O Domhnaill Enterprises Inc. Makes New Investment in Gilead Sciences, Inc. $GILD

O Domhnaill Enterprises Inc. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 15,198 shares of the biopharmaceutical company’s stock, valued at approximately $2,118,000. Gilead Sciences comprises about 1.7% of O Domhnaill Enterprises Inc.’s investment portfolio, making the stock its 24th biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC lifted its holdings in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.9%

Shares of NASDAQ GILD traded up $5.04 during midday trading on Tuesday, reaching $134.65. 2,408,275 shares of the company’s stock were exchanged, compared to its average volume of 7,199,889. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The business’s fifty day moving average price is $129.44 and its two-hundred day moving average price is $134.64. The stock has a market capitalization of $167.17 billion, a PE ratio of 18.32 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on GILD shares. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $133.00 to $155.00 in a research note on Monday. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Finally, Truist Financial reduced their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday. Twenty-six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.19.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock valued at $10,824,500 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.